First Look at Control-IQ: A New-Generation Automated Insulin Delivery System
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To pilot test a new closed-loop control technology to validate it for a further large clinical trial. RESEARCH DESIGN AND METHODS: The t:slim X2 insulin pump with Control-IQ Technology (Tandem Diabetes Care) includes a Dexcom G6 sensor and a closed-loop algorithm implemented in the pump that 1) automates insulin correction boluses, 2) has a dedicated hypoglycemia safety system, and 3) gradually intensifies control overnight, aiming for blood glucose levels of approximately 100–120 mg/dL every morning. RESULTS: Five patients with type 1 diabetes (mean age 52.8 years, 2/3 male/female, mean A1C 6.5%) used Control-IQ in an outpatient setting (hotel) for approximately 37 h. During the closed loop, mean glucose was 129 mg/dL (135/121 mg/dL during the day/night), time within target range 70–180 mg/dL was 87% (82%/94% during the day/night), and time <60 mg/dL was 1.1% (2.0%/0.0% during the day/night). CONCLUSIONS: Following this pilot trial, Control-IQ was deployed in several studies, including the large-scale National Institutes of Health International Diabetes Closed-Loop (iDCL) Trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 8×
“In terms of system connectivity, the CGM signal was available 94.4% of the time and closed loop was running without interruption 98.4% of the time.”
MethodInfluentialSelf-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“A pivotal trial was completed of the first commercial hybrid AP systemdtheMedtronic 670G, which automatically modulates basal rate but does not automate insulin correction boluses (6)dand the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invested in four large projects intended to bring AP s…”
BackgroundBreton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M. (2017) · Diabetes Care · doi:10.2337/dc17-0883 · Cited by 179 · cited 2×
“, Europe, Israel, and Argentina, which ensured external validity of the data (2,3,5,7,8,13,14).”
BackgroundSelf-citationKovatchev, B., Cheng, P., Anderson, S. M., Pinsker, J. E., Boscari, F., Buckingham, B. A., Doyle, F. J., Hood, K. K., Brown, S. A., Breton, M. D., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0333 · Cited by 141
Self-citationMultinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120
Self-citationRenard, E., Farret, A., Kropff, J., Bruttomesso, D., Messori, M., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0008 · Cited by 104
Self-citationThe Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes
Kovatchev, B., Tamborlane, W. V., Cefalu, W. T., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc16-0824 · Cited by 95
Self-citationDel Favero, S., Boscari, F., Messori, M., Rabbone, I., Bonfanti, R., Sabbion, A., Iafusco, D., Schiaffini, R., Visentin, R., Calore, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2815 · Cited by 94
The year of transition from research to clinical practice
Kovatchev, B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.170 · Cited by 48 · cited 1×
“A pivotal trial was completed of the first commercial hybrid AP systemdtheMedtronic 670G, which automatically modulates basal rate but does not automate insulin correction boluses (6)dand the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invested in four large projects intended to bring AP s…”
BackgroundSelf-citation
Cited by
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationAdvances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Dicembrini, I., Cosentino, C., Monami, M., Mannucci, E., & Pala, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01589-3 · Cited by 106
A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm
Messer, L. H., Berget, C., & Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0105 · Cited by 100
“Control IQ is currently undergoing pivotal clinical research trials at our Center and others.(21) The language used in the tables is intended to standardize terminology for advanced diabetes device features: low glucose suspend, PLGS, HCL, and traditional insulin pump.”
Method
Metadata
- Authors
- Brown, S., Raghinaru, D., Emory, E., & Kovatchev, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-10-10
- Volume
- 41
- Issue
- 12
- Pages
- 2634-2636
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2895916350
- Cited by
- 82
- References
- 9
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.